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Abstract
Background: Copy number variations (CNV) are important causal genetic variations for human disease; however, the lack of
a statistical model has impeded the systematic testing of CNVs associated with disease in large-scale cohort.
Methodology/Principal Findings: Here, we developed a novel integrated strategy to test CNV-association in genome-wide
case-control studies. We converted the single-nucleotide polymorphism (SNP) signal to copy number states using a well-
trained hidden Markov model. We mapped the susceptible CNV-loci through SNP site-specific testing to cope with the
physiological complexity of CNVs. We also ensured the credibility of the associated CNVs through further window-based
CNV-pattern clustering. Genome-wide data with seven diseases were used to test our strategy and, in total, we identified 36
new susceptible loci that are associated with CNVs for the seven diseases: 5 with bipolar disorder, 4 with coronary artery
disease, 1 with Crohn’s disease, 7 with hypertension, 9 with rheumatoid arthritis, 7 with type 1 diabetes and 3 with type 2
diabetes. Fifteen of these identified loci were validated through genotype-association and physiological function from
previous studies, which provide further confidence for our results. Notably, the genes associated with bipolar disorder
converged in the phosphoinositide/calcium signaling, a well-known affected pathway in bipolar disorder, which further
supports that CNVs have impact on bipolar disorder.
Conclusions/Significance: Our results demonstrated the effectiveness and robustness of our CNV-association analysis and
provided an alternative avenue for discovering new associated loci of human diseases.
Citation: Chen X, Li X, Wang P, Liu Y, Zhang Z, et al. (2010) Novel Association Strategy with Copy Number Variation for Identifying New Risk Loci of Human
Diseases. PLoS ONE 5(8): e12185. doi:10.1371/journal.pone.0012185
Editor: Philip Awadalla, University of Montreal, Canada
Received March 9, 2010; Accepted July 20, 2010; Published August 20, 2010
Copyright:  2010 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National High Technology Research and Development Program of China (No. 2006AA02Z330), the National Basic
Research Program of China (Nos. 2007CB512202, 2007CB512100 and 2004CB518603), the National Natural Science Foundation of China, Key Program
(No. 30530450) and the Knowledge Innovation Program of the Chinese Academy of Sciences (No. KSCX1-YW-R-74). This study uses data generated by the
Wellcome Trust Case-Control Consortium; funding for the project was provided by the Wellcome Trust (Award 076113). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xykong@sibs.ac.cn
Introduction
Copy number variations (CNV) are DNA segments with gains
or losses in copy number longer than 1 kb compared to a reference
genome. At least 12% of the human genome has been identified as
copy number variable [1] and expression correlation studies have
revealed that these pervasive CNVs may affect physiological
function through regulating gene expression [2]. Increasing
evidence has shown that CNVs play important causal roles in
human diseases. For example, CCL3L1-related segmental dupli-
cation influences susceptibility to HIV-1/AIDS [3]. CNVs at
1q21.1 were associated with neuroblastoma [4]. What is more, de
novo CNVs have been associated with autism [5] and sporadic
schizophrenia [6].
The increasing functions found for CNVs in human diseases
make a genome-wide systematic survey of CNVs become
intriguing. However, there are no such effective tools for testing
the association of CNVs with disease in genome-wide scale.
Although many challenges have been reviewed previously [7,8],
here we re-emphasize the challenges in establishing such statistical
model. First, CNVs have a genomic localization pattern that spans
thousands of nucleotides, thus comparison among a chromosomal
region may be more effective than the specific testing on a
designated nucleotide. However, it is hard to pre-define the range
required for comparison in a large case-control dataset, since the
range is closely related to the function of the DNA segment.
Second, traditional association methods mostly summarized
single-nucleotide polymorphism (SNP) allele intensity into raw
copy number signal. However, the multiple Gauss-like distribution
of the raw copy number signal among cases and controls, which
has been recognized in other studies [1,7,8] and in our data
manipulation, demands a complicated statistical model with
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tions will not be suitable for every test, and parameters for these
assumptions that are inferred from experience will not be
applicable to every analysis. Those two challenges together with
the complexities that originate from signal noise, summarization
declination (which occurs when combining the SNP’s alleles with
non-linear measurements) and batch bias (which is from unequal
influence of individual selection and experimental condition),
make it difficult to analyze CNV-association in a uniform one-step
test. Additionally, one-step CNV-association testing, especially
through complicated signal summarization, causes intractable
results that cannot be compared to the primary data, whereas
verification of association results from primary data is important in
genome-wide association studies to provide the confidence for the
findings by common consent.
Here, we developed an integrated strategy to test CNV-
association with disease in large-scale case-control studies in
which single-nucleotide polymorphisms were used to calculate the
copy numbers. Our strategy processed the data in a hierarchical
mode to address the challenges individually (schematically
illustrated in Figure 1 and detailed in Materials and
Methods). We transformed continuous signal into discrete copy
number to eliminate signal noise and slight batch bias. We
performed a SNP specific testing with triple null hypotheses
(named as SNP site-based testing) to conform to pathophy-
siologically functioning way of CNV. We also conducted a
geographical pattern-comparison of CNV (named as window-
based testing) to ensure confidence. We applied this strategy to
genome-wide data with seven common diseases from the Well-
come Trust Case-Control Consortium (WTCCC) [9]. In the
original paper of these data, they found 24 independent associated
signals and several moderate significant signals through genotype-
association testing that was mostly applied in classical genome-
wide association study. By using SNP site-based testing and further
window-based testing, we identified 36 new susceptible loci for
these seven diseases, and none of which were reported previously
to be affected by CNVs. Through data querying for physiological
mechanisms and genotype-association, 15 of these identified loci
were reported to be relevant with those diseases, which indicate
that our results are valuable for further disease-related studies.
Results
Two features of our CNV-association strategy were proved
effective in the following results. The first is the multiple
hypotheses for the functioning mode of CNVs in disease. CNVs
Figure 1. CNV-association strategy transforms raw signal into copy number and detects association through site-specific testing
and CNV-pattern clustering. (A) Relative intensity was log2-transformed value for the normalized intensity-sum of the SNP alleles. (B) the relative
allele-ratio was actually a normalized anti-tangent value for the intensity ratio of SNP alleles. These two measurements were arranged along the
chromosomal sequence as a hidden Markov model. (C) In this model (with well-trained parameters), the copy number could be calculated from the
measurements on each SNP site and the neighboring copy numbers. (D) The copy numbers of a designated site for cases and controls were classified
before performing the SNP site-based testing, a Chi-squared test with triple NULL hypotheses in which deletion (labeled as Loss), amplification
(labeled as Gain) or both (labeled as Abnm) were viewed as abnormal. Copy numbers in a window centered to the significant SNP site (denoted in
the orange box) were subjected to a complete linkage clustering (E). To this clustering heat map, a statistical test on the CNV-pattern (named as
window-based testing) was used to reconfirm the significance of association. (See details in the Materials and Methods.)
doi:10.1371/journal.pone.0012185.g001
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as the common CNV-loci for the gene PDPR [8], while most
CNVs’ deletion and amplification may not be consistent to the
genes’ down-regulation and over-expression. The most important
reason is that most CNVs do not embrace the whole DNA
segments of one gene, but just located or truncated in the coding,
intron, enhancer or insulator region. Deletion and amplification in
these CNVs may just prohibit the gene’s expression or disable the
gene’s function with aberrant isoforms. Thus, the complex roles of
deletion and amplification should be carefully considered in the
association testing. Here, we hypothesized that deletion and/or
amplification contribute to the gene function separately to cope
with its complexity. CNVs may also affect diseases through their
distribution tendency between cases and controls; therefore, three
kinds of trend tests were applied to test the CNVs’ association with
disease (Text S1). The second feature is comparison of the CNV’s
geographical pattern between cases and controls. Our method
applied a window-based chromosome-along clustering algorithm
to the candidate CNV-loci, and then tested these clustering results
statistically. The accidental signal noise could be easily excluded
through the clustering procedure, and the credible CNVs from
common ancestry or with identical physiological significance tend
to congregate around nearby nodes in the clustering heat map.
The statistical testing on these congregated CNVs is more accurate
than SNP site-based testing, and provides further confidence to
our results.
How to confirm the significance of multiple tests for CNV-
association is another focus of our strategy. The CNV-association
P values are different from common P values in multiple tests, in
that these P values tend to be related with the neighboring sites,
which is a phenomenon caused by the geographical stretch of
CNVs. Thus, the classical Bonferroni correction is not suitable. A
permutation method based on the actual data was required to
generate the theoretical distribution of multiple P values. Here, we
hypothesized that the case-control effect size for every loci is null,
and the difference of measurements originate from individual
selection. We permuted the labels of cases and controls,
recalculated the association P values, and then computed the false
discovery rate (FDR) to educe the appropriate significance level for
the association results (see details in Materials and Methods).
Genome-wide CNV-association results
When the FDR was set to less than 0.05 for each hypothesis in
the SNP site-based testing, 2488 SNP sites with P values above the
significance level were obtained for further window-based testing
(Figure 2A). With an FDR of 2.35610
23 for the window-based
testing, we identified 401 disease susceptible SNP sites as disease
susceptible, in which 219 SNP sites were non-redundant
(Figure 2B, Table S1): 43 are associated with bipolar disorder
(BD; MIM 125480), 17 with coronary artery disease (CAD; MIM
607339), 5 with Crohn’s disease (CD; MIM 266600), 41 with
hypertension (HT; MIM 145500), 61 with rheumatoid arthritis
(RA; MIM 180300), 37 with type 1 diabetes (T1D; MIM 222100)
and 15 with type 2 diabetes (T2D; MIM 125853). Thirty-six
CNV-loci were identified from these SNP sites through combining
neighboring SNP sites (Table 1).
We found that SNP sites in close proximity to one another
tended to have similar levels of significance (Figure 2C, Figure
S1). These results indicate that these SNP sites belong to the same
copy number variable region and that these convergent associa-
tions are unlikely to be random events. The high quality of the
final clustering heat map provides confidence for these susceptible
CNV-loci, and the relatively clean CNV-pattern boundaries in the
clustering heat map also indicates the high credibility of these
CNVs (Figure S4). Some of the susceptible CNV-loci in our study
are associated with multiple diseases (Table 1), which is consistent
with the results obtained in the WTCCC genotype-association
study (such as that rs6679677 is significant in RA and T1D) [9].
Biological relevance of the risk loci
To further confirm the effectiveness of our strategy, we
performed data mining within a 0.2-Mb region (which is an
empirical estimation that regulatory elements have a median
distance of 0.1 Mb away from the coding sequence [10,11])
around the centered significant SNP sites for their functional
relationships with corresponding diseases from previous publica-
tions. Fifteen CNV-loci were previously reported to be functionally
related to or be associated with the investigated diseases (Table
S2). For example, CEACAMs (Carcinoembryonic antigen-related
cell adhesion molecule 4, 7, 21) are matrix molecules localized at
the apical glycocalyx of normal colonic epithelium. They are
bacteria receptors [12,13] and have multiple roles in the
pathogenesis of Crohn’s disease [14,15]. Another example is
CASP9 (MIM, 602234), which participates the immune attack in a
murine model of type 1 diabetes [16].
Obvious physiological relevance of these results was observed in
the susceptible genes identified for bipolar disorder, including
INPP5B (MIM, 147264), POU3F1 (MIM, 602479), MTF1 (MIM,
600172), CCDC91 (coiled-coil domain containing 91), KCNQ5
(MIM 607357) and Olfactory receptors (OR4K5, OR4K2, OR4M1,
OR4K1, OR4N2, OR4K14, OR4K13; 14q11.2). INPP5B hydrolyzes
the calcium-mobilizing second messenger inositol 1,4,5-trispho-
sphate (IP3), which is a signal-terminating reaction in the calcium/
IP3 pathway and may directly affect neurophysiologic regulation
[17]. In this locus, deletion is prevalent in the cases (Figure S4A),
which make sense that deletion might down-regulate the INPP5B
expression, leading to inability of terminating the excited calcium
flux. POU3F1, also known as Oct6, plays a crucial role in
neurodevelopment and has been shown to be potentially relevant
in schizophrenia [18]. POU3F1 was also proved to affect calcium
flux through binding to the promoter region of PIK3C3 (MIM
602609), a member of the phosphatidylinositide 3-kinase family,
and mutations in PIK3C3 have been shown to be involved in a
subset bipolar disorder and schizophrenia patients [19]. MTF1
binds to the metal responsive element, which is regulated by
lithium salts in the treatment of bipolar disorder [20] and may also
interact with cytosolic calcium [21]. More than 1% of the cases
could be confirmed with deletion in 12p11.22 (Figure S4C). The
gene CCDC91 in this locus may affect protein sorting and
membrane trafficking through interacting with GGAs (Golgi-
localized, Gamma ear-containing, ARF-binding proteins) [22]. It
has been found that many members in the same pathway of
CCDC91 are associated with bipolar disorder, and its binding
partner AP1G1 was up-regulated in the post-mortem cerebellum
of schizophrenia patients [23,24]. KCNQ5 (potassium voltage-gated
channel subfamily KQT member 5) may contribute to episodic
disturbances of mood and behavior as well-characterized roles in
other ion-channelopathies [25], and two family members, KCNC2
and KCNQ2, were found to be associated with bipolar disorder
[9,26]. What is more, KCNQ5 is connected to phosphoinositide
signaling through regulation by PIP5K2A(MIM 603140), a
schizophrenia-associated gene [27]. Olfactory receptors, which
belong to the G-protein coupled receptor 1 family, may play some
roles in intracellular aberrant calcium mobilization of olfactory
neurons in bipolar patients [28]. The CNV-association signifi-
cances of those seven olfactory receptors also match the nearby
genotype association (rs7159947, trend P value=4.91610
24,
genotypic P value=2.02610
23) in the WTCCC paper [9].
Risk Loci for Common Diseases
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can also be used to explain the substantial olfactory deficits in
patients with schizophrenia [29], a psychotic disorder related to
bipolar disorder.
Therefore, all those associated genes listed above are related to
phosphoinositide/calcium pathway (whose interaction-relationship
is illustrated in Figure S5), which strongly suggests the role of this
pathway in bipolar disorder. Moreover, detailed analysis of these
associated genes (Figure S4A, B, C) implicated that CNVs with
similar boundary and pattern might play roles in the inheritance of
bipolar disorder.
Our strategy found disease-associated CNV-loci from the
SNP sites that were omitted by traditional genotype-
association analysis
CNVs are different genetic variations from SNPs, in that they
are deletion or amplification of DNA fragments but not single-
nucleotide polymorphisms. Here, we compared our CNV-
association results with SNP genotype-association in WTCCC.
There was little tendency-accordance between the both results on
SNP site level (Figure S2), which reflects that CNV-association
are unique from genotype-association and could be new way in
Figure 2. Thresholds for the significance of CNV-association and genome-wide distribution of the results in bipolar disorder. (A)I n
the SNP site-based testing, 1000 permutations were performed and the boundary P values (Psnp) were plotted against the false discovery rate (FDR)
values, with different colors indicating the different hypotheses (blue for Abnm, green for Loss and red for Gain). FDR,0.05 (labeled with vertical
dashed line) for each hypothesis was used to select 2488 SNPs as candidates for the window-based testing. (B) In the window-based testing, 25000
permutations were performed and the resulting P values (Pwin) were plotted against the FDR values. 401 SNP sites were selected as the final results,
with an FDR of 2.35610
23 (indicated by the vertical dashed line) to ensure that the false positives in all the results were less than 1. (C) The 2log10 of
the SNP site-based P values were plotted against the position on each chromosome. The three hypotheses are plotted in different panels, and the P
values of the chromosomes are shown in alternating colors for clarity. The P values that passed the SNP site-based testing are highlighted in green,
and the P values that passed the window-based testing are highlighted in yellow. The genome-wide distribution results for the seven diseases are in
Figure S1.
doi:10.1371/journal.pone.0012185.g002
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the associated genes, we found that potassium voltage-gated
channel subfamily (KCNQ5 in CNV-association and KCNC2 in
genotype-association), olfactory receptors could be found in the
both results.
One interesting finding is that a large proportion (25.1%) of
our results were absent in genotype-association analysis
(Figure 3A, B, C, Figure S2 and Table S1). This
phenomenon results from two limitations of genotype association:
the genotyping model in the association test is limited to three
genotypes (AA, BB, AB) and the genotyping quality is dependent
on the sample-wide intensity mapping of the A and B alleles. Both
of these limitations are not suitable for SNPs in copy number
variable regions with chaotic intensity mapping and with
genotypes not limited to three (shown by the sample-wide
intensity maps in Figure 3D and Figure S3). Similar
phenomenon of CNVs’ effect on genotype-association has been
found in the locus of CYP2D6 in breast cancer [30], and it has
been pointed out that CNVs in this locus should be assessed
before genotype-association analysis [31].
Table 1. CNV-loci associated with seven diseases.
Disease Chromosome Landmark Loss Abnm Gain Window-based Trend Genotypic
BD 1p34.3 rs16824514 7.55610
25 1.06610
24 3.83610
21 1.16610
25 1.58610
21 1.42610
21
BD 6q13 rs4991400 2.29610
24 2.29610
24 1.00 2.29610
24 6.73610
21 8.78610
21
BD 12p11.22 rs10843150 1.60610
25 4.90610
25 1.00 1.60610
25 8.26610
21 9.59610
21
BD 12p11.21 rs4931443 1.00 2.98610
25 2.98610
25 1.36610
25 NA NA
BD 14q11.2 rs2635556 3.34610
21 7.55610
25 1.36610
24 1.58610
25 NA NA
CAD 3p26.1 rs163968 2.01610
24 2.01610
24 1.00 2.01610
24 9.16610
21 8.46610
21
CAD 7q21.11 rs10245061 4.85610
28 4.85610
28 1.00 4.85610
28 2.62610
21 2.10610
21
CAD 16q22.1 rs2303200 1.64610
22 3.93610
24 8.98610
27 8.98610
27 NA NA
CAD 19q13.2 rs2016070 1.51610
21 9.54610
23 1.39610
25 1.39610
25 NA NA
CD 19q13.2 rs1015758 2.31610
21 1.94610
23 1.00610
24 4.88610
25 NA NA
HT 1p31.1 rs596204 2.85610
25 2.85610
25 1.00 2.85610
25 2.02610
21 6.05610
22
HT 2q13 rs3906021 1.52610
24 2.03610
24 1.00 5.36610
25 9.52610
21 5.78610
21
HT 5q12.1 rs4302532 2.14610
24 2.14610
24 1.00 2.14610
24 6.65610
21 6.79610
21
HT 5q22.1 rs152875 5.08610
25 2.65610
25 5.20610
21 8.98610
25 NA NA
HT 10p14 rs263431 2.21610
24 2.21610
24 1.00 1.67610
24 1.00 1.00
HT 10q25.3 rs2419854 1.34610
24 1.34610
24 1.00 1.69610
24 2.70610
21 5.33610
21
HT 11q12.2 rs175126 2.26610
23 2.26610
23 1.00 5.20610
25 2.70610
21 4.24610
21
RA 1q23.3 rs10917851 1.95610
24 7.55610
25 3.88610
21 1.95610
24 1.94610
21 4.28610
21
RA 2q31.2 rs2303836 7.55610
25 7.55610
25 1.00 7.55610
25 5.91610
22 6.26610
23
RA 7p21.3 rs1467345 1.31610
23 1.31610
23 1.00 6.14610
26 6.68610
21 9.12610
21
RA 7q21.11 rs10245061 8.20610
28 8.20610
28 1.00 8.20610
28 8.04610
21 4.09610
21
RA 8p11.1 rs12550215 2.92610
25 1.40610
25 3.06610
21 2.92610
25 9.92610
21 1.01610
21
RA 9p23 rs10977624 2.92610
25 2.92610
25 1.00 1.95610
24 1.86610
21 3.96610
21
RA 15q13.3 rs2926504 8.46610
27 1.07610
25 4.11610
21 8.46610
27 2.40610
21 2.64610
21
RA 16q22.1 rs2303200 2.75610
21 1.18610
23 1.05610
24 6.67610
25 NA NA
RA 19q13.2 rs2016070 9.17610
21 1.23610
24 6.19610
26 6.19610
26 NA NA
T1D 1p36.13 rs6429757 8.75610
26 6.20610
26 1.00 8.75610
26 4.43610
21 6.86610
21
T1D 1q41 rs337147 9.51610
27 8.85610
25 1.00 9.51610
27 5.66610
21 6.62610
21
T1D 2p14 rs13409606 1.06610
25 1.06610
25 1.00 1.06610
25 NA NA
T1D 5q22.1 rs524203 5.68610
24 3.11610
24 5.20610
21 1.58610
24 8.76610
21 9.77610
21
T1D 10p15.3 rs2210553 1.00610
25 1.00610
25 1.00 1.00610
25 5.49610
21 3.16610
21
T1D 14q11.2 rs10873018 1.70610
27 1.20610
27 1.00 1.70610
27 6.26610
23 2.00610
23
T1D 15q11.2 rs2880332 8.88610
26 3.29610
21 4.74610
22 1.13610
24 NA NA
T2D 1p34.3 rs16824514 1.52610
23 1.64610
22 5.22610
21 2.35610
24 6.35610
21 8.86610
21
T2D 1q41 rs337147 3.65610
26 1.17610
23 4.13610
21 3.65610
26 9.61610
21 8.03610
21
T2D 19q13.2 rs2016070 5.79610
25 3.64610
26 4.44610
23 5.79610
25 NA NA
Notes: Landmark is the representative SNP site in the associated CNV-loci. Loss, Abnm and Gain denote the three hypotheses in the SNP site-based testing, in
which deletion, amplification and both were tested respectively; Window-based is the P values from the window-based testing; Trend and Genotypic indicate the
genotype-association P values in the WTCCC paper, and missing P values in both of the tests are labeled with ‘‘NA’’ for Not Available. A detailled list of SNP sites that
were associated with diseases could be found in the Table S1. Seven diseases were tested with CNV-association in the present work, which are bipolar disorder (BD),
coronary artery disease (CAD), Crohn’s disease (CD), hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D) and type 2 diabetes (T2D).
doi:10.1371/journal.pone.0012185.t001
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In the present study, we have shown that our two-level CNV-
association testing is a reliable strategy to search for risk CNV-loci.
This method is complement to the traditional genotype-association
analysis, and provides a unique way to discover new causes for
human diseases. Our results provide further evidence that CNVs
involve in many common diseases. In addition, the new risk CNV-
loci identified in our work will be helpful on understanding the
pathogenesis of these diseases.
The functions of CNVs are interesting topics in disease-risk
study, the complexity of which has been mentioned previously
[1,8], but they are far from being fully understood. Linear-effect
model is the most common hypothesis on how CNVs function in
disease, and the findings in the CNV-loci 16q22.1 (Armitage trend
test P value=3.98610
28, the trend also shows in clustering heat
map) can support this hypothesis: amplification of two genes
(PDPR and AARS) in 16q22.1 might impose a counteractive effect
on CAD, while loss of copy number may cause weaker recovery
from heart attack as they function in post-ischemic heart [32,33].
However, most loci have more complicated association with
disease. Loss of copy number in the gene INPP5B may induce
leakage-cleanup of IP3 in the nerve conduction, and then induce
patients to lose control of excited emotion, while gain of copy
number shows no obviously effect in bipolar disorder. In 14q11.2,
a common copy number variable region, copy number differen-
tiation may produce irregular isoforms of olfactory receptors, and
then causes mis-perception in the olfactory and neuronal cells.
Pattern discordance could be found in many CNV-loci of RA and
T1D, which might be from aberration of DNA recombination and
repair in somatic and germ cells. The CNVs with pattern
discordance may make an impact on these diseases by interfering
the genes’ functions explicitly or through cell-recognition in
complicated immune pathway. In a word, copy number variations
may work in very complex way in the development of disease, and
the function of risk CNV-loci need a locus-by-locus analysis.
Materials and Methods
Disease data and training set
Two Affymetrix Mapping 500K chip datasets were used in the
present work, which include the Wellcome Trust Case-Control
Figure 3. Comparison with the traditional genotype-association analysis demonstrates the priority of our method in CNV-regions.
‘‘Gen’’ labels the genotypic testing (a Chi-squared test with 2 degrees of freedom) results obtained from the WTCCC paper [9]. The 2log10 of SNP
site-based P values in our study with the triple NULL hypotheses, in which deletion (A, labeled Loss), amplification (C, labeled Gain) and both (B,
labeled Abnm) were evaluated separately, are plotted against the 2log10 of the P value from the genotype-association test of WTCCC [9]. For clarity,
the genotype-association P values,10
25 are highlighted in green, the CNV-association P values that passed the single SNP site-based testing are in
blue, and the CNV-association P values that passed the window-based testing are in red. The SNP sites that are absent from the genotype-association
testing are plotted by default as zero (highlighted in brown), and the absent sites that passed the SNP site-based testing are labeled with black. The
genotypic testing (Gen) and trend testing (Add, another testing for genotype tendency of disease in WTCCC [9]) for the seven disease are compared
with our CNV-association results in Figure S2.( D) Evidence that CNVs can lead to chaotic genotyping clusters in copy number variable regions. All
the 17000 individuals are labeled with grey, individuals with CNVs in the disease group are in red, and individuals with CNVs in controls are in green.
More evidence of chaotic sample-wide intensity maps affected by CNVs can be found in Figure S3.
doi:10.1371/journal.pone.0012185.g003
Risk Loci for Common Diseases
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comprising 2000 cases and 3000 normal control individuals) [9]
and a training data of 90 individuals in Utah, USA, from the
Centre d’Etude du Polymorphisme Humain collection (abbrevi-
ated as CEU, which is of Northern and Western European
ancestry) [34]. The WTCCC data was used to test the association
of the CNVs with disease. Individuals from the WTCCC data
were filtered following the instructions in the paper [9] in order to
avoid contamination, false positives, non-Caucasian ancestry and
relatedness. Based on the multi-scale comparison between the
CEU data and WTCCC data in the original paper [9], the CEU
data was selected as the training set to estimate the parameters of
the hidden Markov model. The CEU data was quantile
normalized to the WTCCC data as described in the WTCCC
paper [9].
We processed the data using SNPs annotated in the NCBI build
35 and build 36 reference databases, and the results in the different
builds were almost the same. In the main text and supporting
information, results were only shown for build 35. Since the sex
chromosomes are different from autosomes in copy number
detection and comparison, only the autosomes were tested in our
work.
Strategy of CNV-association with one-step data
transformation and two-pass statistical testing
CNVs are mostly detected from SNP genotyping data, thus a
precise transformation from SNP allele intensity into copy number
is essential in testing the association between CNVs and diseases.
In our work, a powerful hidden Markov model that makes the best
of the SNP allele information was applied. To make sure that the
parameters of hidden Markov model were suitable for all the high-
throughput dataset of WTCCC, we developed a training program
to calculate these parameters. This hidden markov model is
depicted in the Figure 1A, B, C, and is detailed in the following
text.
The significance of the CNVs was evaluated in two levels of
statistical tests: (i) SNP site-based testing to measure the
disease-association on a specific SNP site and (ii) Window-based
testing to measure the CNV-pattern differentiation in and
around the selected SNP site. Additionally, multiple trend
testing was also applied for exploring CNV-association with
disease (see details in Text S1). The SNP site-based testing was
used to selected candidate for window-based testing, and the
window-based testing ensured the credibility of the identified
CNV-loci. This statistical flow chart is shown in Figure 1C, D, E
and is detailed in the following text.
Transformation of SNP signal to copy number
The SNP data from the genotyping chips was first converted to
copy number (hidden copy number state) using a well-trained
hidden Markov model. The hidden Markov model treated the
series of SNP sites, which were arranged along the chromosome
sequence, as a hidden Markov chain. The copy number
calculation on the site of the hidden Markov chain is dependent
on the signal of each SNP site and the copy number of
neighboring SNP site. Two measurements for each SNP site were
used to calculate its copy number: (i) the Log R Ratio (LRR),
which is the log2-transformed value for the normalized intensity-
sum of the SNP alleles, and (ii) the B allele frequency (BAF), which
actually is a normalized anti-tangent value for intensity-ratio of the
SNP alleles. The expected value for each SNP genotype cluster
and intensity-sum, which were used in the normalization for LRR
and BAF, were the 90% trimmed mean of all of the corresponding
values from the WTCCC samples. All of the measurements and
transformations above were calculated according to the instruc-
tions from the original technical paper [35], but the copy number
used in the following case-control association analysis was the total
copy number integer from the hidden Markov state in the original
technical paper [35]. For example on a certain SNP site, the CNV
genotype is ‘‘AAB’’, which had a copy number of 3 and belonged
to state 5 in the original paper; but here we use 3 to denote the
CNV genotype.
The hidden Markov model needs a series of parameters to
calculate the hidden Markov state, including the LRR’s expecta-
tion (and standard deviation) for each state, the BAF’s expectation
(and standard deviation) for each state, the transition probability
matrix for inferring relationship among SNP-series, and other
parameters. These parameters were trained from the CEU data of
HapMap and the program was performed automatically to
eliminate bias from manual selection in the original technical
paper [35]. Before estimation, hidden states of the training set
were assigned with initial values of these parameters, and CNVs
that spanned at least three continuous SNP sites were treated as
real variations to eliminate coincidence from noise. The LRR’s
expectation for each state was determined by linear extrapolation.
The LRR’s standard deviation calculated from SNP sites with two
copies was adopted for all other states, as we assumed that noise
plays similar roles in every state and this could be seen in the
actual data distribution. The BAF’s expectation and standard
deviation for every state were inferred from the data distribution of
the previous state calling. Transition probability for the hidden
Markov model was calculated using the Baum-Welch algorithm,
and a chromosome-weighted mean was used as the actual
transition probability. Repetition of the estimation program was
performed using the newly generated values of these parameters,
until constant values were obtained independently of the initial
values, with a change of ,0.0001 for every parameter.
SNP site-based testing for site-specific significance
The influence of changes in copy number (amplification and/or
deletion) on physiological function is far from fully understood, so
testings for amplification, deletion or the both were used to
measure the significance on single SNP site. We postulated triple
NULL hypotheses that (i) amplification (denoted as Gain), (ii)
deletion (denoted as Loss) or (iii) the both (denoted as Abnm) show
no difference between the case and control groups. For a certain
SNP site, the copy numbers of cases and controls could be
summarized in Table 2.
If N denotes the total number of cases and controls, ri denotes
the sum of the rows and cj denotes the sum of columns, the
Table 2. The numbers of cases and controls in SNP site-based
testing.
Gain cn§3 ðÞ
Loss cnƒ1 ðÞ
Z Norm Abnm cn=2 ðÞ
Cases n11 n12
Controls n21 n22
Notes: Z is the number of samples, cn is the copy number of individuals. Gain,
Loss and Abnm denote the three hypotheses, in which amplification, deletion
and the both were tested separately. Norm is the number of the samples that
exclude those with CNVs tested. The element of this table, nij, is the number of
individuals in the different conditions.
doi:10.1371/journal.pone.0012185.t002
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ricj
N . The P value
could be calculated from the following chi-squared distribution
with one degree of freedom:
x2~
X nij{eij
   2
eij
If any of the eij values were less than 5, a Fisher’s exact test was
applied instead. If ri and cj are constant in the permuted
contingency table and n
m ðÞ
ij is number of the elements in
permutation, the exact P value for one permutation can be
calculated as follows:
P m ðÞ ~
Pri!:Pcj!
N:Pn
m ðÞ
ij
Then the Fisher’s exact P value is calculated as follows:
Pfisher~
X
P m ðÞ ƒPobserved
P m ðÞ
Window-based testing for CNV-patterns
Window-based testing was based on clustering heat map of
CNV-pattern, which can test the CNV-association in and around
the specific SNP site. In this testing, copy number, which was
generated from random noise or possessed irregular pattern, could
be eliminated. For an individual, a series of SNP sites in a window
centered on a specific site were extracted to measure the CNV-
region. This region can be described by vectors, such as that vx
and vy denote vectors from different individuals.
vx~vector x1,x2,   ,xn ðÞ
vy~vector y1,y2,   ,yn ðÞ
In vectors vx and vy, x and y are used to denote the copy numbers
for the series of SNP sites in the selected region. n is the dimension
of the vector, which is the same as the window size. Based on the
distribution of the lengths of CNVs along chromosomes in the
actual data, n was set to 41 in the present work to bracket the most
CNVs in the corresponding region. The Euclidean distance
between vx and vy was adopted in the clustering method, and a
complete linkage clustering algorithm [36] was modified slightly to
accelerate the computation speed in our work. The distance
calculation and clustering method above were selected through
visual analysis using some example data.
All the vectors clustered in an unbiased manner between the
cases and controls. If Z denotes the number of samples, Nodej
denotes a certain node in the clustering relationship tree and
ReNode denotes the remaining samples apart from those in
Nodej. The data obtained for every node could be summarized
into contingency Table 3.
A Chi-squared test could be applied to this table, but when nij
were less than 5, the Fisher’s exact test was used instead. The P
value could be calculated in the same way for the contingency
table in SNP site-based testing.
For every node in the clustering tree, a corresponding P value
could be calculated. The node for the most significant P value was
defined as ‘‘First class node’’, and then the corresponding P value
was named as ‘‘First class P value,’’ which was also defined as the P
value for the window-based testing.
First class P value~ min
1ƒjƒn
P value of nodej
   
The First class P value, which is the most significant using different
divisions in the vector dimensions, is the only reasonable
measurement to scale the CNV differentiation between cases
and controls, since we cannot predefine the actual dimensional
division.
Correction of multiple tests by calculating false discover
rates (FDR)
A permutation-based method was used to obtain the signifi-
cance level for the SNP site-based testing. In the permutation
procedure, the labels of the cases and controls were randomly
permuted 1000 times, and then the P values for all of the diseases
were pooled together to calculate the FDR. Psite denotes a
designated P value in the observed data, P and P m ðÞdenote the P
values in the observed data and permutated data respectively, Nsnp
denotes the number of SNP sites and Tpm denotes the number of
permutations. The FDR for the SNP site-based testing can be
calculated using the following formula.
FDRsite~
N
snp
P m ðÞ ƒPsite
Tpm:N
snp
PƒPsite
The P value in the window-based testing was not only dependent
on the neighboring SNP sites but also built upon the clustering
structure. To filter out the false positives obtained in multiple tests,
we assumed that the copy number windows (which were labeled
with the centered SNP sites) possess similar statistical power in all
the diseases and all the window-based P values were pooled to
calculate the FDR. FPwin denotes a designated P value in the
observed data, FP and FP m ðÞdenote the P values in the observed
data and permuted data respectively, Nwin denotes the number of
copy number window and Twin denotes the number of
permutations. After the labels for the case and control were
permuted 25000 times, the FDR for the window-based testing was
calculated as follows:
FDRwin~
Nwin
FP m ðÞ ƒFPwin
Twin:Nwin
FPƒFPwin
Table 3. The numbers of cases and controls in window-based
testing.
Z Nodej ReNode
Cases n11 n12
Controls n21 n22
Notes: CNV-pattern is classified in the window-based chromosome-along
clustering process and is organized in different nodes of the clustering heat
map. Z is the number of samples, and Nodej denotes the number of cases or
controls in the specific node in the clustering heat map. ReNode denotes the
number of samples that exclude those in the Nodej. The element of this table,
nij, is the number of individuals in the different conditions.
doi:10.1371/journal.pone.0012185.t003
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observed data) by the corresponding FDR could provide the
estimation of false positives from random coincidence of individual
selection. In the SNP site-based testing, FDR,0.05 was used to
determine the proper number of candidates for the window-based
testing. In the window-based testing, the boundary of the FDR was
adjusted to ensure that false positives in the final results were less
than 1 copy number window (centered SNP site).
Supporting Information
Supporting information include supporting data with five figures
and two tables, and supporting methods in Text S1. The code for
the data transformation and the two-level CNV-association tests
was written in the C/C++ programming language. This code and
the manual for the data processing are available at http://www.ihs.
ac.cn/xykong/CNV_Association_Test.rar.
Supporting Information
Figure S1 The genome-wide distribution of the CNV-association
results in the seven diseases. The 2log10 of the SNP site-based P
values in our testing with the three hypotheses, in which deletion
(labeled asLoss),amplification (labeled as Gain)and both (labeled as
Abnm) were evaluated as abnormal separately, are plotted against
the position on each chromosome. For clarity, P values that passed
theSNPsite-basedtesting arehighlightedingreenandthe SNP sites
that passed the window-based testing are highlighted in yellow.
Found at: doi:10.1371/journal.pone.0012185.s001 (1.10 MB
DOC)
Figure S2 Comparison with the previous genotype-association
analysis demonstrates the priority of the CNV-association test in
copy number variable regions. ‘‘Gen’’ and ‘‘Add’’ indicate the
genotypic test and trend test, respectively, in the WTCCC paper.
The 2log10 of the SNP site-based P values in our test with the triple
NULL hypothesis (Loss, Abnm and Gain) were plotted against the
2log10 of the P values from the genotype association test from the
WTCCC (A–G). For clarity, the genotype association P val-
ues,1025 are highlighted in green, the CNV-association P values
that passed the single SNP site-based testing are in blue and the
CNV-association P values that passed the window-based testing are
in red. SNPs absent from the genotype association analysis are
plotted by default as zero and highlighted in brown, in which many
SNPs that passed the SNP site-based testing are labeled with black.
Found at: doi:10.1371/journal.pone.0012185.s002 (0.78 MB
DOC)
Figure S3 Evidence that CNVs can lead to chaotic genotyping
clusters in copy number variable regions. The selected sample-wide
intensity maps show the typical influence of CNVs in the seven
diseases labeled with abbreviations (A–F). All of the 17000 individuals
are labeled with grey, individuals with CNVs in the disease group are
in red and individuals with CNVs in controls are in green.
Found at: doi:10.1371/journal.pone.0012185.s003 (0.49 MB
DOC)
Figure S4 Selected CNV-loci that show strong evidence of
association with diseases. The 2log10 of the SNP site-based P values
are plotted against the genomic location, in which the SNPs that
passed the window-based testing are indicated in dark blue for the
deletion hypothesis, dark green for the amplification hypothesis and
orange for the deletion and amplification hypothesis. SNPs that
lacked significance are shown in light colors (light blue for deletion,
light green for amplification and yellow for both). Functionally
affected regions were characterized within a 0.2 Mb region centered
on the identified SNP sites, and the region boundary (vertical dashed
line) coincided with the length limitations or the location of
neighboring genes. The clustering heat map for 41 SNP windows
(each corresponding to the upper CNV-region) demonstrated good
CNV boundaries in and around the ‘‘first class node.’’ In the heat
map, black indicates a copy number of 0, red a copy number of 1,
light grey a copy number of 2 and green a copy number of 3.
Found at: doi:10.1371/journal.pone.0012185.s004 (6.21 MB
DOC)
Figure S5 Thecartoon depicts the functionofthecalcium-related
pathway in bipolar disorder. The Ca2+/IP3 pathway has been
reported to be closely related to bipolar disorder, and the molecules
revealed in previous studies are labeled with blue circles and in red
font. IP3 precursors in the membrane and metabolites in the cytosol
are denoted by different shaped boxes. INPP5B, POU3F, Olfactory
receptors (belonging to GPCR, G Protein-Coupled Receptors) and
KCNQ5, which were found to be associated to CNVs in our work,
are labeled with black font and orange circles (or boxes).
Found at: doi:10.1371/journal.pone.0012185.s005 (0.09 MB
DOC)
Table S1 List of SNP sites showing significance in the window-
based testing.
Found at: doi:10.1371/journal.pone.0012185.s006 (0.63 MB
DOC)
Table S2 22 risk genes that were validated from previous studies.
Found at: doi:10.1371/journal.pone.0012185.s007 (0.20 MB
DOC)
Text S1 Supporting methods of multiple testing for trend.
Found at: doi:10.1371/journal.pone.0012185.s008 (0.08 MB
DOC)
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